Argon-mediated cytoprotective effects are abolished after TLR2 and TLR4 inhibition.

<p>Annexin V positive and PI negative cells [%] of rotenone-induced apoptosis and consecutive argon treatment (n = 8; mean±SD; rotenone 19.4±0.7 vs. rotenone+argon 75 Vol% [2 h] 13.1±1.4; *** = p<0.001), <b>(A)</b> with TLR2 inhibitor (TAK-242; rotenone+argon 75 Vol% [2 h] 13.1±1.4 vs. TAK-242+rotenone+argon 75 Vol% [2 h] 16.9±1.0; ** = p<0.01 and rotenone 19.4±0.7 vs. TAK-242+rotenone+argon 75 Vol% [2 h] 16.9±1.0 and TAK-242+rotenone 18.5±1.6 vs. TAK-242+rotenone+argon 75 Vol% [2 h] 16.9±1.0; both * = p<0.05) or <b>(B</b>) TLR2 and TLR4 inhibitor (OxPAPC; rotenone+argon 75 Vol% [2 h] 13.1±1.4 vs. OxPAPC+rotenone+argon 75 Vol% [2 h] 18.1±2.9; *** = p<0.001, rotenone 19.4±0.7 vs. OxPAPC+rotenone+argon 75 Vol% [2 h] 18.1±2.9 and OxPAPC+rotenone 18.6±1.5 vs. OxPAPC+rotenone+argon 75 Vol% [2 h] 18.1±2.9; both n.s. = not significant). <b>Argon-mediated phosphorylation of IRAK4 is abolished after TLR2 and TLR4 inhibition. (C)</b> Densitometric analysis and representative Western blot image of IRAK4 protein phosphorylation after rotenone treatment. Equal loading was confirmed by reprobing with total-IRAK4 and analysis was performed in relation to the corresponding protein (n = 8; mean±SD; untreated 0.70±0.13 vs. rotenone 1.21±0.19; *** = p<0.001; rotenone 1.21±0.19 vs. rotenone+argon 75 Vol% [2 h] 0.80±0.13; ** = p<0.01 and rotenone+argon 75 Vol% [2 h] 0.80±0.13 vs. OxPAPC+rotenone+argon 75 Vol% [2 h] 0.92±0.2; * = p<0.05).